Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)!
You May Also Like:: Adagrasib as Monotherapy or With Cetuximab for KRAS-Mutated Colorectal Cancer
Pembrolizumab offered long-term efficacy in patients with non-small cell lung cancer (NSCLC), as shown by a 5-year survival rate of 26.9 months.
Key Findings:
Introduction: Real-World Data on Pembrolizumab’s Long-Term Efficacy Is Limited
Pembrolizumab is a front-line treatment for advanced NSCLC with a PD-L1 TPS of ≥ 50%. However, there is scarce real-world evidence of the long-term efficacy of PD-L1 inhibitor monotherapy in NSCLC patients with a high PD-L1 expression.
To address this knowledge gap, a study published in the Journal for ImmunoTherapy for Cancer assessed the 5-year outcomes of a real-world cohort of patients with advanced NSCLC and PD-L1 TPS ≥ 50% who received first-line pembrolizumab monotherapy.
Methodology: Cohort Study
This study assessed the 5-year outcomes of 1,050 patients from 61 institutions across 14 countries (referred to as Pembro-real 5Y). Individual patient-level data (IPD) were also extracted from the KN024 trial experimental arm to compare the long-term outcomes of the two cohorts. The researchers also created a “KN024 look-alike” cohort by excluding patients with
an Eastern Cooperative Oncology Group-performance status (ECOGPS) status of ≥ 2 to assess the reproducibility of clinical trial results. Conditional inference tree analysis was performed to provide a hierarchical organization of long-term benefit determinants.
Results:
At the 5-year landmark, 282 patients were alive, resulting in a 5-year survival rate of 26.9%. The median overall survival (OS) was 21.8 months (95% confidence interval (CI): 19.1–25.7, 805 events), while the real-world progression-free survival (rw-PFS) was 10.4 months (95% CI: 8.5–11.8, 862 events). The overall response rate (ORR) was 49.6% (95% CI: 45.2%–54.2%).
Of 962 evaluable patients, 59 experienced a complete response to treatment (6.1%, 95% CI: 4.6%–7.9%). At the data cut-off, 32 patients (54.2%) were progression-free.
Conditional inference tree analysis showed that ECOG-PS was the strongest determinant for an increased risk of death (p < 0.001), as those with poor PS only had a 5-year survival rate of 12.7% (95% CI: 7.9%–20.3%).
Among patients with an ECOG-PS 0–1, the second determinant was age (p = 0.024), with those aged < 70 years having a 5-year survival rate of 33.8% (95% CI: 28.1%–40.2%).
Patients with an ECOG-PS 0–1, aged ≥ 70 years, and a PD-L1 tumor proportion score (TPS) between 50% and 89% had a 5-year survival rate of 18.6% (95% CI: 13.1%–25.6%). The 5-year survival rate for patients with a PD-L1 TPS ≥ 90% was 33.7% (95% CI: 22.9%–47.8%) (p = 0.028).
Conclusion: Pembrolizumab Offers Real-World, Long-Term Efficacy
This real-world study substantiated the long-term efficacy of pembrolizumab, a finding that was also observed in the KN024 trial, while emphasizing the broader demographics and other challenges present in real-world practice. The analysis also showed the hierarchical role of baseline clinicopathological factors, with ECOG-PS being the most significant predator of treatment benefit, followed by age and PD-L1 expression.
Source:
Cortellini, A., Brunetti, L., Di Fazio, G. R., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., Gettinger, S., Kim, S. Y., Jayakrishnan, R., Zarif, T. E., Russano, M., Pecci, F., Federico, A. D., Awad, M., Alessi, J. V., . . . Hejleh, T. A. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry. Journal for Immunotherapy of Cancer, 13(2), e010674. https://doi.org/10.1136/jitc-2024-010674
For more insights visit: https://mdnewsline.com/
